Send us a text

Josh Haimson is Co-Founder and CEO of Inductive Bio ( https://www.inductive.bio/about ), a technology company focused on democratizing artificial intelligence (AI) models to transform small molecule drug discovery, eliminating Absorption, Distribution, Metabolism, Excretion and Toxicology (ADMET) bottlenecks with state-of-the-art AI models and generative chemistry, powered by a unique pre-competitive data consortium.

Josh has spent his career focused on the intersection of machine learning, product, and life sciences/healthcare.

Prior to Inductive, Josh was the Director of Product for the ML and data curation organizations at Flatiron Health, where his teams worked to generate real-world evidence (RWE) at scale across Flatiron’s network of over 2 million active cancer patients for use by researchers in pharma, academia, and government.

Prior to Flatiron, Josh was at MIT studying computer science and working with researchers at Massachusetts General Hospital to use ML and NLP to predict patient response to cardiac resynchronization therapy.

#JoshHaimson #InductiveBio #SmallMolecule #DrugDiscovery #Absorption #Distribution #Metabolism #Excretion #Toxicology #ADMET #AI #GenerativeChemistry #MachineLearning #CardiacResynchronizationTherapy #MolecularGlue #FlatironHealth #PreCompetitiveDataConsortium #RealWorldEvidence #RealWorldData #RWE #ArtificialIntelligence  #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #Research

Support the show